AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00535730 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23
Description: Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
Study NCT00739349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVA22007 ''Cyclosporine''
Description: Cyclosporine 0.05% Ophthalmic Cationic Emulsions
Study NCT00739349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVA22007 ''Cyclosporine''
Description: Cyclosporine 0.1% Ophthalmic Cationic Emulsions
Study NCT00739349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle/placebo
Description: vehicle/placebo
Study NCT02119507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: Single application on Day 0
Study NCT02119507 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment - control
Study NCT00754026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of interscalene catheter for shoulder surgery
Description: Distance of interscalene catheter: 2cm
Study NCT00754026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of interscalene catheter for shoulder surgery
Description: Distance of interscalene catheter: 6cm
Study NCT03576157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kilkari
Description: Kilkari is an outbound service that delivers weekly, time-appropriate audio messages about pregnancy, childbirth, and childcare directly to families on their mobile phones, starting from the second trimester of pregnancy until the child is one-year-old.
Study NCT00430768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-CB-hAAT
Study NCT03728673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oral Capsules
Description: Active capsules will contain 10 mg escitalopram oxalate.
Study NCT04192981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily
Study NCT04192981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiation therapy radiation
Description: 30Gy in 10 fractions
Study NCT03390439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd-Yap 1340nm laser
Description: Each part of the abdomen will be treated with a therapeutic modality. The ND-yap 1340-nm laser will be used in the following parameters: 90 mtz / cm2 nozzle, 90 mJ / mtz power, 2.5 Hz frequency, 3 ms pulse duration, 1 pass.
Study NCT01902641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
Study NCT02028260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg daily
Study NCT02028260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar appearing inert tablet
Study NCT00606385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: Laparoscopic or Open hepatectomy
Study NCT00606385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: Laparoscopic or Open hepatectomy
Study NCT02127411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention
Description: The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
Study NCT02251457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranexa is FDA approved for chronic angina
Study NCT03390439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: In the other segment of the abdomen, the dermaroller 2.5 mm will be applied, with ten to fifteen passes in the same direction and at least four crosses in the rolling areas.
Study NCT03568864 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low nucleotide meal
Description: The participants will consume a mixed meal (sandwich) containing a nucleotide depleted mycoprotein product (low in nucleotides)
Study NCT03568864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High nucleotide meal
Description: The participants will consume a mixed meal (sandwich) containing a non nucleotide depleted mycoprotein product (high in nucleotides)
Study NCT02654808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirSeal trocar
Description: The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes.
Study NCT02654808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard trocar
Description: A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas.
Study NCT04037501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Management
Description: A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
Study NCT04180618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal health wallet service for emergency situation
Description: Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
Study NCT01509898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water jet
Description: use of water jet for a month
Study NCT04435665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFX-179 Gel
Description: gel for topical administration
Study NCT04435665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: vehicle gel for topical administration
Study NCT00003954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00003954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous bone marrow or PBSCT
Study NCT00003954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Undergo autologous bone marrow or PBSCT
Study NCT00003954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous bone marrow or PBSCT
Study NCT00003954 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00003954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo donor PBSCT
Study NCT00003954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV and PO
Study NCT00003954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT00003954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Undergo DLI
Study NCT04802538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OstoRing®
Description: Participants will use the OstoRing® along with their standard pouching equipment.
Study NCT04351867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus oxaliplatin and capecitabine
Description: docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
Study NCT04351867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin plus capecitabine
Description: oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
Study NCT04214704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genteel lancing device
Description: Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively
Study NCT04214704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genteel lancing device
Description: Painless lancing device that helps to improve and assess self-monitoring frequency and HbA1c respectively
Study NCT04214704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lancing device
Description: Conventional lancing device
Study NCT04214704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional lancing device
Description: Conventional lancing device
Study NCT04513990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of nasopharyngeal, oral, saliva, and nasal samples
Study NCT02916381 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: General anaesthesia
Study NCT04513990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Demographic information, sample collection type preferences; clinical outcome information
Study NCT03213158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Oral Capsule
Description: Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle. Patients will take ixazomib and dexamethasone for twelve (12) 28-day cycles.
Study NCT01117064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation Therapy Device (NMTD)
Description: Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
Study NCT01117064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation Therapy Device (NMTD)
Description: Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
Study NCT01117064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation Therapy Device (NMTD)
Description: Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
Study NCT03977038 — intervention group
Intervention type: DEVICE
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is prescribed as first-line treatment for TRD patients (4). rTMS is safe, tolerable and non-invasive neurostimulation procedure where powerful magnetic pulses are transmitted through the skull into the underlying cortical cortex with the aim of electrical current induction within the neural tissue. This study administers a standard dose of rTMS treatment to the TRD patient sample consisting of high frequency deep TMS (HF-dTMS) stimulation over left dorsolateral prefrontal cortex (L-DLPFC), at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks. The technology of dTMS, which will be used in this study, is an adaptation of the therapeutic intervention of rTMS with the advancement of possessing higher efficacy in targeting deeper brain regions of interest.
Study NCT01684748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Description: Crossover intervention comparing antihypertensive medication to no drug intervention.
Study NCT03185533 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality improvement (QI) interventions
Description: 1. The ED admissions exhibited prolonged length of stay.~2. The Interventions for Reducing Medical Decision Time:~1. The ED director created QI education sessions and reported monthly QI outcomes.~2. The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~3. The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3. The Interventions for Reducing Boarding Time~1. The ED patients could be admitted before 8 a.m. if the bed was vacant.~2. The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~3. Monthly QI outcomes were reported in the hospital affairs meeting.
Study NCT00970138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib tablet
Description: A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT00970138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: apatinib tablet
Description: A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT03943030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
Study NCT04568434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.
Study NCT04568434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olezarsen-matching placebo will be administered by SC injection.
Study NCT03231085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate or ferrostrane
Description: Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
Study NCT03231085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate or ferrostrane
Description: Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
Study NCT00884585 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine Vehicle
Description: Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
Study NCT00884585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.010%
Description: Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
Study NCT00884585 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporine 0.010%
Description: Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
Study NCT03756051 — intervention group
Intervention type: OTHER
Intervention: Prospective Longitudinal Data
Description: We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have \~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
Study NCT03756051 — intervention group
Intervention type: OTHER
Intervention: Surveys and Semi-structured Interviews
Description: We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family).
Study NCT03746366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [C-11]
Description: Radiolabel
Study NCT03777436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Oral
Study NCT03746366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pittsburgh Compound B
Description: Tracer
Study NCT05729763 — intervention group
Intervention type: OTHER
Intervention: 3D-PADUA nephrometric score
Description: Evaluation of the PADUA nephrometric score with 3D images
Study NCT05729763 — intervention group
Intervention type: OTHER
Intervention: 2D-PADUA nephrometric score
Description: Evaluation of the PADUA nephrometric score with 2D images
Study NCT00827918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8998
Description: MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
Study NCT00827918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Olanzapine
Description: Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
Study NCT00827918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo tablets matching olanzapine tablets and MK-8998 capsules
Study NCT01632748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotech Vital Device
Description: 5 minute treatment
Study NCT01632748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Neurotech Vital Device
Description: 5 minute stimulation
Study NCT04231812 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laparoscopic Tissue Morcellation working space (bag)
Description: The LapBox is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy
Study NCT02806375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Day 0: Infusion of unmanipulated graft
Study NCT02806375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Days -5 through -3: Busulfan 1 mg/kg po qid №10